In a landmark Phase 2 obesity trial, participants receiving the highest dose achieved: Up to ~24% average weight loss at 48 weeks Weight loss had not yet plateaued at the end of the study Potential for even greater reductions with longer treatment duration For context: Semaglutide (GLP-1): ~15% weight loss Tirzepatide (GIP + GLP-1): ~2123% weight loss Retatrutide (GIP + GLP-1 + Glucagon): ~24%+ weight loss in Phase 2 studies Common side effects were similar to other GLP-1based therapies and included nausea, vomiting, diarrhea, constipation, and abdominal discomfort, primarily during dose escalation
Central to this balance is glutathione reductase (GR), which uses nicotinamide adenine dinucleotide phosphate (NADPH) to facilitate the reduction of glutathione disulfide (GSSG) to glutathione (GSH), thus equipping the cell to counteract oxidative stress [10]
Another critical factor is donor hair quality
Semaglutide and tirzepatide are large peptide molecules with molecular weights exceeding 4,000 daltons, a threshold that typically prevents significant transfer into breast milk
California law permits care to be delivered by telehealth, and Business and Professions Code section 2290.5 does not require an initial in-person examination
